Switching to Extended Half-Life Therapies Improves Hemophilia Care, but Raises Short-Term Costs

Switching to Extended Half-Life Therapies Improves Hemophilia Care, but Raises Short-Term Costs

Switching to extended half-life from standard half-life therapies for hemophilia enhances treatment adherence and reduces infusion frequency, despite initial cost increases.

Extended hemophilia half-life products improve care, but raise costs

Adults with hemophilia who switched from standard to extended half-life replacement treatment needed fewer infusions, had fewer bleeds per year, and adhered better to their treatment schedules, a Finnish study shows. Switching to extended half-life replacement treatment increased the mean yearly costs by nearly €19,000 (about $22,000) for hemophilia A patients. The increase in yearly costs was even higher with hemophilia B, by more than €60,000 …